| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Journey Medical Corporation$7.27
+0.15 (+2.11%)
D 36Pipeline Score Fair Value Pharma · Commercial
Market Cap
164.11 M
EPS
-0.38
P/E Ratio
-
Value Trade
1.09 M
SEC Financials
Q1 2026Dilution Risk
Revenue
15.96 M
Operating CF
2.91 M
Total Assets
91.53 M
Total Liabilities
60.70 M
Equity
30.83 M
D/E Ratio
12,345
-2.45 %
Week
17.55 %
1 Month
-29.8 %
3 Month
-20.53 %
6 Month
-31.49 %
5 Year
-31.49 %
All Time
Cash Data
Cash Position
27.22 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
147.34 K
52 Week Range
4.31 - 9.56
% held by Insiders
51.47 %
% held by Institutions
43.92 %
Enterprise Value
162.35 M
Total Shares
21.54 M
Short %
22.39 %
Float Shares
12.04 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Journey Medical Corporation
97Total events
0Upcoming
28Tier-1 (high impact)
2021 – 2026Coverage
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-11-04 | DFD-29 (Minocycline Hydrochloride Modified) | PDUFA Date | PDUFA | Approved | – | – | – |
2024-11-04 | DFD-29 (Minocycline Hydrochloride Modified) | PDUFA Date | PDUFA | Approved | – | – | – |
2024-11-04 | DFD-29 (Minocycline Hydrochloride Modified) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
D36
Pipeline Score $118M
Pipeline ValueFair Value
Valuation Signal7
Drugs Scored0.7x
rNPV / MCap Top 50%
Micro Cap (rank 457 of 912)
Percentile RankJourney Medical Corporation faces pipeline headwinds (36/100), with $473M risk-adjusted pipeline value, led by DFD-29 in Papulopustular Rosacea (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DFD-29 Small molecule | Papulopustular Rosacea | Phase 3 | NCT05343455 | 58% | $162M | COMPLETED | 653 | - | - | Jun 30, 2023 | - | Dec 3, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Emrosi | moderate-to-severe rosacea | Phase 1 | 2025-12-11 | 16 weeks; 60 healthy, adult subjects; 30 males and 30 females; 2:1 randomization between DFD-29 and placebo Read More | Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology Read More | |
Emrosi | moderate-to-severe rosacea | Phase 1 | 2025-12-11 | 16 weeks; 60 healthy, adult subjects; 30 males and 30 females; 2:1 randomization between DFD-29 and placebo Read More | Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology Read More | |
Emrosi | moderate-to-severe rosacea | Phase 1 | 2025-12-11 | 16 weeks; 60 healthy, adult subjects; 30 males and 30 females; 2:1 randomization between DFD-29 and placebo Read More | Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DERM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DERM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DERMJourney Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
Journey Medical Corporation will participate in A.G.P.'s Annual Virtual Healthcare Conference on May 20, 2026. CEO Claude Maraoui is scheduled for a fireside chat at 5:00 PM ET. The company specializes in FDA-approved dermatological products and aims to enhance investor relations through this event.
Read more →DERMJourney Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues for the first quarter ended
Journey Medical Corporation reported a 21% year-over-year increase in total revenues for Q1 2026, reaching $16.0 million. The company highlighted strong demand for its product Emrosi, which is establishing itself as a leading treatment for rosacea. With over $27 million in cash, Journey Medical positions itself well for continued growth and improved operational efficiency throughout the year. Upcoming events include a conference call scheduled for May 13, 2026, to discuss these results further.
Read more →DERMJourney Medical Corporation Secures Contract with Third Major GPO for Emrosi Payer access for Emrosi expanded from approximately 100 million commercial lives to over 150 million commercial lives as of
Journey Medical Corporation has secured a contract with its third major group purchasing organization (GPO), expanding payer access for its product Emrosi from approximately 100 million to over 150 million commercial lives in the U.S. The company reports that 85% of commercial lives now have access to Emrosi, which is approved for treating inflammatory lesions of rosacea in adults. The CEO expressed optimism about the growth potential for Emrosi, anticipating that increased formulary adoption will enhance profitability and reduce reliance on co-pay bridging programs. This development reflects Journey Medical's ongoing commitment to improving patient access to dermatological therapies.
Read more →DERM▼ -30%on this news
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation reported a successful financial year for 2025, with total revenues rising to $61.9 million, up from $56.1 million in 2024. The launch of Emrosi™ contributed significantly, generating $14.7 million in net revenues and achieving approximately 53,000 prescriptions filled. The company highlighted its expanding presence in medical dermatology and optimistic growth prospects for the future.
Read more →DERMJourney Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
Journey Medical Corporation announced the publication of Phase 1 clinical trial results for Emrosi (DFD-29), demonstrating its safety and lack of impact on microbial flora in healthy adults. The study confirmed that Emrosi can be administered for 16 weeks without affecting skin, gastrointestinal, or vaginal microbiota. These findings support Emrosi's use as a treatment for moderate-to-severe rosacea.
Read more →DERM▼ -15.3%on this news
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation reported a strong third quarter for 2025, with net revenues reaching $17.6 million, a 21% increase from the previous year. The company's product Emrosi saw a significant rise in prescriptions, up 146% from the second quarter. CEO Claude Maraoui highlighted the product's clinical success and expanding market adoption, positioning it as a leading treatment for rosacea.
Read more →DERMJourney Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
Journey Medical Corporation presented promising efficacy data for DFD-29, an oral formulation of minocycline, at the 2025 Fall Clinical Dermatology Conference. The Phase 3 trials demonstrated significant improvements in treatment success rates and reduction of inflammatory lesions in rosacea patients compared to both placebo and Oracea. The results highlight Emrosi's potential as a leading treatment option in dermatology.
Read more →DERMJourney Medical Corporation to Participate in October 2025 Investor Conferences
Journey Medical Corporation announced its participation in two investor conferences scheduled for October 2025. The events include the 4th Annual ROTH Healthcare Opportunities Conference and the ThinkEquity Conference, both taking place in New York City. This engagement reflects the company's ongoing efforts to connect with investors and promote its FDA-approved dermatological products.
Read more →DERMJourney Medical Corporation to Present at the Emerging Growth Conference
Journey Medical Corporation (DERM) will present a corporate overview at the Emerging Growth Conference on August 20, 2025. CEO Claude Maraoui will lead the presentation, which will be conducted virtually. The company specializes in FDA-approved prescription products for dermatological conditions and aims to enhance its market presence through this event.
Read more →DERM▲ +8.5%on this news
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter o
Journey Medical Corporation reported strong financial results for the second quarter of 2025, with total revenues of $15 million, including net sales from its newly launched product Emrosi amounting to $2.8 million. The quarter marks the first full period since Emrosi entered the market, which has seen a positive reception from physicians and payers. Additionally, the company announced its inclusion in the Russell 2000 and Russell 3000 Indexes, potentially increasing its visibility. A conference call is scheduled to discuss these results and future plans.
Read more →DERMJourney Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
Journey Medical Corporation is set to ring the Nasdaq closing bell on August 11, 2025, celebrating its four-year anniversary as a publicly traded company. The event coincides with the commercial launch of Emrosi, a new treatment for rosacea. The CEO highlighted the company's progress and confidence in future profitability.
Read more →DERMJourney Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
Journey Medical Corporation has announced that it will release its second quarter 2025 financial results on August 12, 2025. The company will conduct a conference call and audio webcast at 4:30 p.m. ET on the same day. Interested parties can participate by dialing in or accessing the webcast through the company's website.
Read more →DERMJourney Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Journey Medical Corporation has announced that payer coverage for its rosacea treatment, Emrosi, has expanded to 65% of commercial lives in the U.S., up from 29% in May 2025. This increase is expected to drive further growth in prescription demand. The company's CEO expressed optimism about the product's adoption and its potential to become the standard of care for rosacea.
Read more →DERM▲ +8.9%on this news
Journey Medical to Join Russell 2000 and Russell 3000 Indexes Scottsdale, AZ
Journey Medical Corporation (Nasdaq: DERM) announced its inclusion in the Russell 2000 and Russell 3000 Indexes effective June 27, 2025. This move is expected to enhance the company's visibility among investors. Journey Medical's recent product, Emrosi, designed for treating inflammatory lesions of rosacea, is reportedly performing well in the market. The company anticipates that 2025 could be a pivotal year for its growth and expansion.
Read more →DERM▼ -5.5%on this news
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Revenue for the First Quarter Ended
Journey Medical Corporation reported strong financial results for the first quarter of 2025, with revenue reaching $13.1 million. The company successfully launched Emrosi, a new oral rosacea treatment, which showed strong initial prescribing and has gained acceptance in treatment guidelines. Positive Phase 3 clinical trial results for Emrosi were published, contributing to its strong market entry. Journey Medical also reported improved gross margins and reduced operating expenses, signaling an optimistic outlook for sustainable profitability in the coming year.
Read more →DERMJourney Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer Scottsdale, AZ
Journey Medical Corporation has appointed Ramsey Alloush as its Chief Operating Officer, promoting him from his previous role as General Counsel. Mr. Alloush's appointment is seen as key to driving the company's operational strategies and maximizing shareholder value. The company's upcoming launch of the dermatology product Emrosi is anticipated to enhance its market position and provide innovative solutions to patients. Alloush brings over 15 years of experience in the pharmaceutical industry, contributing significantly to Journey Medical's growth during his tenure.
Read more →DERM▼ -5.2%on this news
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights FDA Approval of Emrosi ( 40 mg Minocycline Hydrochloride Modified-Release Capsules ) for Rosacea Emrosi Initial Distrib
Journey Medical Corporation reported its financial results for the year ended December 31, 2024, highlighting a product revenue of $55.1 million, which aligns closely with their guidance. The company achieved FDA approval for Emrosi, a treatment for rosacea, earlier than expected, and has commenced distribution with initial prescriptions filled. Journey Medical's financial performance reflects a focus on enhancing growth and moving towards EBITDA positive status, with promotional activities planned for Emrosi starting in April 2025.
Read more →DERM▲ +13.9%on this newsshared move
Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea Initial distribution of Emrosi to p
Journey Medical Corporation has officially launched Emrosi, a modified-release capsule formulation of minocycline hydrochloride for treating inflammatory lesions of rosacea. The initial distribution to pharmacies has commenced, and the first prescriptions have been filled. Emrosi has received FDA approval and is noted for delivering superior clinical outcomes compared to existing treatments. However, it comes with warnings regarding potential adverse reactions and serious health risks for some patients.
Read more →DERM2025 Journey Medical Corporation. All rights reserved. EMROSI
Journey Medical Corporation is gearing up for the launch of its novel rosacea treatment, Emrosi, which shows superior efficacy compared to existing treatments. The company plans to kick off direct promotions in early April 2025, following the AAD conference, where KOL presentations will take place. Emrosi, developed with an advanced formulation, aims to enhance patient outcomes in managing rosacea. However, the company faces significant market risks including intense competition and reliance on regulatory approvals for commercial success.
Read more →DERMJourney Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights U.S. FDA approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflamma
Journey Medical Corporation reported its third quarter 2024 financial results, highlighting revenues of $14.6 million. A key development was the FDA approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules) for the treatment of inflammatory lesions of rosacea in adults, with a launch anticipated in late Q1 or early Q2 of 2025. The company aims to leverage this approval to enhance its market presence using its experienced sales force. Despite positive developments, Journey Medical faces challenges, including commercializing Emrosi and competition in the dermatology market.
Read more →DERM▼ -13.8%on this news
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea Journey Medical to host investor conference call on Monday
Journey Medical Corporation announced FDA approval for Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for treating inflammatory lesions of rosacea in adults. The approval follows successful Phase 3 clinical trials demonstrating its superiority over the current standard treatment. With a focused marketing team ready for the launch, Journey Medical anticipates Emrosi to become a leading oral treatment option in the dermatological market. A conference call is scheduled for November 4, 2024, to discuss the approval details.
Read more →DERM▼ -15.3%on this news
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of
Journey Medical Corporation reported its financial results for the second quarter of 2024, revealing a revenue increase to $14.9 million, marking a 14% rise from the previous quarter. The company announced its New Drug Application for DFD-29 to treat rosacea is under FDA review, with a PDUFA goal date set for November 4, 2024. The leadership expressed optimism regarding future financial performance and strategic corporate advancements, including new key appointments within the team.
Read more →DERMJourney Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of
Journey Medical Corporation announced its financial results for Q1 2024, reporting a 7% increase in revenue driven by key products. The company’s New Drug Application for DFD-29, indicated for rosacea, was accepted by the FDA, with a PDUFA goal date set for November 4, 2024. Despite these positive developments, Journey Medical faces challenges, including reliance on product development success and competition from generics. The company aims to leverage its existing infrastructure for the launch of DFD-29 to capture market opportunities.
Read more →DERMJourney Medical Corporation Appoints Joseph Benesch as Chief Financial Officer Scottsdale, AZ
Journey Medical Corporation has appointed Joseph M. Benesch as its Chief Financial Officer, effective April 26, 2024. Previously serving as Interim CFO since January 2023, Benesch brings over 25 years of financial leadership experience, notably in the pharmaceutical sector. CEO Claude Maraoui expressed confidence in Benesch's capabilities, particularly regarding the company’s upcoming milestones, such as the anticipated approval of DFD-29 for rosacea treatment. The appointment underscores the firm’s commitment to strategic leadership as it navigates its market initiatives.
Read more →DERMJourney Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Company generated total revenues of $79.2 million for the full year ended
Journey Medical Corporation announced its financial results for the full year of 2023, reporting total revenues of $79.2 million, a 7% increase from 2022. The company achieved significant operating cost savings and reported an accepted New Drug Application for its rosacea treatment candidate, DFD-29, which has a PDUFA goal date of November 4, 2024. The CEO highlighted the successful expansion of their product reach and improvements in cost structure, setting the stage for future growth. However, the company also reported a net loss, albeit reduced from the previous year, and a decline in cash compared to 2022.
Read more →DERM▼ -5.7%on this news
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million Provides additional capital for general corporate purposes including funding to support the potential launch of DFD-29 Scottsdal
Journey Medical Corporation has secured a credit facility with SWK Holdings for a maximum of $20 million, aimed at providing additional capital for its corporate purposes. This financing will primarily support the potential launch of DFD-29, preparing for a New Drug Application submission pending FDA approval. The facility features an initial term loan of $15 million and an option for an additional $5 million depending on the achievement of specified metrics. The funding is expected to enhance Journey Medical's operational flexibility and strengthen its balance sheet.
Read more →DERM▲ +5.5%on this news· ran to +16% by day 1
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 mill
Journey Medical Corporation reported strong financial results for Q3 2023, marked by total net revenues of $34.5 million, which represent a 101% increase from the previous quarter. The company also posted a GAAP net income of $16.8 million, a significant improvement from a loss of $10.1 million during the same period in 2022. Journey Medical highlighted the positive topline results from two Phase 3 clinical trials for DFD-29, with an NDA expected to be filed with the FDA by year's end. The recent licensing agreement with Maruho Co., Ltd. for Qbrexza adds to their financial strength.
Read more →DERM▲ +18.7%on this news· ran to +35% by day 3
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza in South Korea and Other Asian Nations Journey to receive an upfront payment of $19 million Scottsdale, AZ
Journey Medical Corporation has entered into an exclusive licensing agreement with Maruho Co., Ltd. to develop and commercialize Qbrexza for the treatment of hyperhidrosis in South Korea and other Asian nations. The agreement includes a nonrefundable upfront payment of $19 million to Journey. Maruho will bear all development and commercialization costs. Additionally, the existing agreement between the two companies has been amended to adjust certain royalty obligations, while Journey remains eligible for milestone payments.
Read more →DERM▲ +12.1%on this news
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2
Journey Medical Corporation reported a 41% increase in net revenues to $17.2 million for Q2 2023. This growth was bolstered by positive results from two Phase 3 clinical trials for DFD-29, which showed superior efficacy over the current standard of care. The company plans to submit a New Drug Application to FDA for DFD-29 in the second half of 2023. Despite strong revenue growth, Journey Medical recorded an $8.4 million net loss and faced challenges with cash reserves due to operational costs and impairments.
Read more →DERMJourney Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Achieved "Last Patient Out" milestone in Phase 3 clinical program evaluating DFD-29 in May 2023 Topline data are ex
Journey Medical Corporation has reported its financial results for the first quarter of 2023, highlighting a revenue of $12.2 million. The company achieved a key milestone with the 'Last Patient Out' in the Phase 3 clinical trials for DFD-29, with topline data expected in June 2023. Journey Medical anticipates a return to revenue growth and significant reductions in SG&A expenses, aiming for savings exceeding $12 million compared to 2022. However, the company also faces challenges related to lower sales volumes for some products and pressures from competition.
Read more →DERM▼ -6.6%on this news
Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights Generated record total revenues of $73.7 million for the full year 2022 Completed enrollment in Phase 3 clinical progra
Journey Medical Corporation announced its financial results for the full year 2022, reporting record revenues of $73.7 million. The company completed enrollment in a Phase 3 clinical trial for DFD-29 aimed at treating papulopustular rosacea, with topline data expected in the first half of 2023. Despite challenges such as generic competition and supply chain issues, Journey Medical is optimistic about revenue growth from several products in 2023 and plans to file a New Drug Application for DFD-29 later this year.
Read more →DERM▼ -7.6%on this news
Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer Scottsdale, AZ
Journey Medical Corporation announced the appointment of Joseph Benesch as Interim Chief Financial Officer, effective January 27, 2023, following the resignation of Ernest De Paolantonio. Benesch, who has over 25 years of experience, has been with the company as Corporate Controller since November 2021. The company anticipates important milestones this year, including topline data from their DFD-29 Phase 3 clinical trials and plans to file an NDA afterward. De Paolantonio will assist in a smooth transition until March 31, 2023.
Read more →DERMJourney Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Revenue for the first nine months of 2022 increased 26% to $57.7 million versus the same period in 2021 of $45.6 mi
Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights for the first nine months of 2022 increased 26% to $57.7 million versus the same period in 2021 of $45.6 million Phase 3 studies are 75% enrolled to date data from the Phase 3 clinical pro
Read more →DERMJourney Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 stud
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 studies 45% enrolled to date; 9 additional sites underway in Europe open to enro
Read more →DERM▼ -5.3%on this news
Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights Generated record revenue of $23.3 million for the first quarter of 2022 First patient dosed in Phase 3 clinical pro
Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights Generated record revenue of $23.3 million for the first quarter of 2022 in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea Company
Read more →DERMJourney Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights Generated record net product revenues of $63.1 million for the full year 2021 Completed initial public offering of comm
Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights Generated record net product revenues of $63.1 million for the full year 2021 Completed initial public offering of common stock and raised $30.6 million in net proceeds in P
Read more →DERMJourney Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST) Franchise from VYNE Therapeutics, Inc. Franchise includes AMZEEQ for the treatment of acne and
Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST) Franchise from VYNE Therapeutics, Inc. AMZEEQ for the treatment of acne and ZILXI for the treatment of rosacea, and a development-stage dermatology progr
Read more →DERM▲ +5.6%on this news
Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights Generated record net revenues of $19.6 million for the third quarter of 2021 Completed initial public offering of c
Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights Generated record net revenues of $19.6 million for the third quarter of 2021 Completed initial public offering of common stock and raised $31.2 million in net proceeds S
Read more →Competitive Position
How DERM ranks across every disease it competes inCompetitive Position is a premium feature
See how DERM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial